Immunocompromised patients still experience unpredictable courses of COVID-19, despite
that effective vaccines and drugs against SARS-CoV-2 are now available. Antiviral …

Background In immunocompromised patients, persistent SARS-CoV-2 viral shedding and
relapsing COVID-19 pneumonia have been described. Currently, little is known about the …

Immunocompromised patients with leukemia/lymphoma often have a suboptimal response
to vaccination against SARS-CoV-2 and, if infected, can develop a persistent infection …

Vaccines remain the cornerstone of medical prevention and are highly effective in reducing
the risk of severe disease and death due to coronavirus disease 2019 (COVID-19). In the …

COVID-19 in immunocompromised patients is difficult to treat. SARS-CoV-2 interaction with
the host immune system and the role of therapy still remains only partly understood. There …

Despite global vaccination efforts, immunocompromized patients remain at high risk for
COVID‐19‐associated morbidity. In particular, patients with impaired humoral immunity …

This study aimed to compare the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) with
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …

Abstract Nirmatrelvir/ritonavir (NMV‐r) is an effective anti‐SARS‐CoV‐2 agent and has been
recommended in the treatment of nonhospitalized patients with COVID‐19. In rare …

Background Morbidity and mortality are higher in immunocompromised patients affected by
COVID-19 than in the general population. Some authors have successfully used antiviral …

Post-acute sequelae of SARS-CoV-2 (PASC) or long COVID is a major public health
problem. The underlying mechanism (s) of this disease remains unclear, and there is a lack …